Tchaikapharma High Quality Medicines AD

BUL:THQM Stock Report

Market Cap: лв1.6b

Tchaikapharma High Quality Medicines AD Valuation

Is THQM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of THQM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: THQM (BGN17.5) is trading above our estimate of fair value (BGN0.13)

Significantly Below Fair Value: THQM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for THQM?

Key metric: As THQM is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for THQM. This is calculated by dividing THQM's market cap by their current revenue.
What is THQM's PS Ratio?
PS Ratio32.2x
Salesлв49.85m
Market Capлв1.61b

Price to Sales Ratio vs Peers

How does THQM's PS Ratio compare to its peers?

The above table shows the PS ratio for THQM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.8x
SFA Sopharma AD
0.5xn/aлв957.9m
A185750 Chong Kun Dang Pharmaceutical
0.7x3.0%₩1.2t
603367 Cisen Pharmaceutical
1.6xn/aCN¥6.7b
688513 Chengdu Easton Biopharmaceuticals
4.5x22.4%CN¥5.9b
THQM Tchaikapharma High Quality Medicines AD
32.2xn/aлв1.6b

Price-To-Sales vs Peers: THQM is expensive based on its Price-To-Sales Ratio (32.2x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does THQM's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
THQM 32.2xIndustry Avg. 3.1xNo. of Companies33PS0612182430+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: THQM is expensive based on its Price-To-Sales Ratio (32.2x) compared to the European Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is THQM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

THQM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio32.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate THQM's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Novavax

US$1.3b

A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.

NVV1

US$6.70

7D

-21.8%

1Y

22.0%

Evotec

€1.8b

Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.

EVT

€8.82

7D

0%

1Y

n/a

Valneva

€343.9m

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

AYJ

€2.08

7D

-9.8%

1Y

-61.5%